DZ Bank’s Clearside Biomedical CLSD Stock Holding History

DZ Bank’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,000	Closed	-$483K	–	894
2018 Q1	$483K	Buy	+3,000	New	+$365K	﹤0.01%	796

Other funds holding CLSD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

DZ Bank's CLSD Position: Q2 2018 in Review

DZ Bank sold out of Clearside Biomedical (CLSD) in Q2 2018, closing a stake of 3,000 shares — an estimated $483K sold.

DZ Bank first reported a position in CLSD in Q1 2018 and held it in 1 quarter. The position peaked at $483K in Q1 2018. 86 funds tracked by Wall St. Rank hold CLSD as of Q2 2018.

DZ Bank reported no remaining Clearside Biomedical position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 3,000 Clearside Biomedical shares in Q2 2018, an estimated $483K.
DZ Bank first reported a position in Clearside Biomedical in Q1 2018 and held it in 1 quarter.
DZ Bank's Clearside Biomedical position peaked at $483K in Q1 2018.
86 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.